IDEA Pharma appoints UPenn research specialist to New York practice

IDEA Pharma appoints UPenn research specialist to New York practice

IDEA Pharma is delighted to announce the appointment of Rick Ritacco as Account Manager, joining the New York practice to work with the company's East Coast client base.

With a firm grounding in neuroscience and business, Rick joins IDEA direct from the University of Pennsylvania where he was a research specialist tasked with leading and managing multi-million dollar programs around the neural controls of energy expenditure. (Hence Rick's IDEA name of Brainy IDEA…)

Commenting on his new role, Rick said: "I have always been interested in the intricacies of successful strategic positioning and working across a multitude of therapy areas, and IDEA's reputation for delivering outstanding strategy within this landscape is second-to-none. I am thrilled to join the New York team, not to mention the overall global team, and look forward helping to actively grow the business further."

"Rick joins IDEA at a really exciting time of growth in the more innovative companies in the US. He has already demonstrated his ability to hit the ground running and embodies our company ethos perfectly, adding to our creative pool of mavericks, rebels and geniuses," said IDEA's CEO, Mike Rea.                

End

About IDEA Pharma:

IDEA Pharma is the industry leader in path-to-market design at phase II, turning molecules into commercially successful products. Past Work Includes: Over 75% of the products FiercePharma labeled as 'Blockbuster Contenders' in pipelines in October 2011; Over 50% of the 50 fastest-growing drugs in 2005-2010.

Jonathan Crosby
Marketing and Communications Director


Direct tel: +44 (0) 1234 756 343
Mobile: +44 (0) 7545 538 901
Skype: jonathanmartincrosby

Suggested Articles

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.

Keytruda's U.S. NSCLC sales might start to fall as soon as early 2020, one analyst says, as I-O rivals eat into its share based on recent successes.

A small group of physicians expressed little interest in new MS drugs from Novartis, Merck KGaA and Biogen but favored a repurposed therapy.